The growing interest in potent weight management has resulted in considerable investigation into groundbreaking treatments. Currently, Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist , has exhibited promising results in clinical trials, implying potential for substantial weight loss . As a re